What is the share price of Fresenius Kabi Oncology Ltd (FKONCO)?

Company share prices are keep on changing according to the market conditions. The current trading price of Fresenius Kabi Oncology Ltd (FKONCO) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Fresenius Kabi Oncology?

The latest standalone P/E ratio of Fresenius Kabi Oncology as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Fresenius Kabi Oncology Ltd (FKONCO)?

The latest standalone P/B ratio of Fresenius Kabi Oncology Ltd (FKONCO) as of 01-Jan-1970 is 3.87.

What is the 52-week high and low of Fresenius Kabi Oncology Ltd (FKONCO)?

The 52-week high of Fresenius Kabi Oncology Ltd (FKONCO) is Rs. 132.60 and the 52-week low is Rs. 132.00.

Fresenius Kabi Oncology Ltd (FKONCO) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Fresenius Kabi Oncology Ltd (FKONCO)
Brand: Fresenius Kabi Oncology

Fresenius Kabi Oncology Ltd (FKONCO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532545 NSE: FKONCO Pharmaceuticals & Drugs | Small Cap | Fresenius Kabi Oncol Share Price

Fresenius Kabi Oncology Ltd (FKONCO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532545 NSE: FKONCO Pharmaceuticals & Drugs | Small Cap | Fresenius Kabi Oncol Share Price

Key Metrics

Valuation Multiples

Market Cap

₹2,255 Cr.

Current Price

₹0

52-Week Low / High

₹132 / 133

TTM EPS

₹-3.2

TTM Sales

₹660 Cr.

Book Value per Share

₹34.3

P/E Ratio

0.00

Industry PE

46.5

Price to Book (P/B)

3.87

Price to Sales (P/S)

3.42

EV/EBITDA

20.53

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

5.47%

Return on Capital Employed (ROCE)

7.33%

Return on Assets (ROA)

3.88%

Operating Profit Margin

15.8%

Net Profit Margin

9.24%

Gross Profit Margin

18.9%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

3.38%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

16.47%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

38.62%

Asset Quality

Promoter Holding

97.05%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹566 Cr.

Equity

₹17 Cr.

Face Value

₹1

All Time Low / High

₹27.05 / 193.75

Fresenius Kabi Oncology stock performance

Key Ratios

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-8.1%	4.3%	6.8%	-2.7%	4.6%	-40.5%	6.7%	4.8%	5.4%	7.3%	-
Value Creation Index ⓘ	-1.6	-0.7	-0.5	-1.2	NA	NA	NA	NA	NA	NA	-
Growth Parameters ⓘ
Sales ⓘ	542	624	703	660	630	603	667	717	786	813	660
Sales YoY Gr.	-	15.2%	12.7%	-6.2%	-4.5%	-4.3%	10.7%	7.5%	9.7%	3.4%	-
Adj EPS ⓘ	-3.4	0.2	2.9	0.8	2.5	-4.6	1	1	1.2	1.4	-3.2
YoY Gr.	-	NA	1731.3%	-73.7%	224.7%	-282.4%	NA	-7.8%	27.4%	16.5%	-
BVPS (₹) ⓘ	25.9	25.8	26.9	23.9	23.9	3.5	25.6	26.6	27.8	29.4	34.3
Adj Net Profit ⓘ	-57	2.8	49.8	13.1	41.3	-75.3	49.6	45.5	58.1	67.8	-54
Cash Flow from Ops. ⓘ	7.9	-39.1	112	98.4	77	0	-460	23.7	175	-63.8	-
Debt/CF from Ops. ⓘ	53.1	-13.3	4.3	4.7	6.2	32629.1	-0.1	6.4	0.9	-1.9	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	4.6%	5.2%	6.8%	3.4%
Adj EPS ⓘ	NA	-10.8%	11%	16.5%
BVPSⓘ	1.4%	4.2%	4.7%	5.7%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-11.9	0.6	11.1	3	10.3	-33.2	7.7	3.6	4.5	4.9	-10
Op. Profit Mgn % ⓘ	1.1	13.9	19.1	13.8	14.8	13.6	14.8	11.2	14.6	15.8	-16.5
Net Profit Mgn % ⓘ	-10.5	0.4	7.1	2	6.6	-12.5	7.4	6.4	7.4	8.3	-8.2
Debt to Equity ⓘ	1	1.2	1	1.1	1.2	10.2	0	0.1	0.1	0.1	-
Working Cap Days ⓘ	438	409	427	473	507	574	604	651	618	594	305
Cash Conv. Cycle ⓘ	198	185	176	168	160	221	265	316	289	334	156

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	541.56	624.01	703.48	659.57	629.87	602.59	667.27	717.14	786.43	813.05
Operating Expenses ⓘ +	553.36	539.64	572.43	569.14	545.94	524.13	588.60	637.93	676.91	685.51
Manufacturing Costs	86.54	85.18	75.96	75.56	72	65.80	60.62	67.31	66.19	69.46
Material Costs	241.68	251.71	273.60	269.24	243.47	228.65	282.10	327.70	360.06	362.84
Employee Cost	115.61	124.43	143.21	143.47	148.39	163.60	161.53	164.72	183.28	182.56
Other Costs ⓘ	109.53	78.32	79.67	80.87	82.08	66.07	84.34	78.20	67.38	70.65
Operating Profit ⓘ	-11.80	84.38	131.05	90.43	83.93	78.46	78.67	79.21	109.51	127.55
Operating Profit Margin (%)	-2.2%	13.5%	18.6%	13.7%	13.3%	13.0%	11.8%	11.0%	13.9%	15.7%
Other Income ⓘ +	12.77	11.65	28.20	41.88	36.24	36.23	38.12	39.05	28.49	35.20
Exceptional Items ⓘ	-18.62	-8.54	-40.13	-102.23	-22.57	-369.41	0	0	0	0
Interest ⓘ	29.21	36.63	45.86	36.80	39.89	37.31	16.45	9.98	6.73	9.51
Depreciation ⓘ	52.10	48.71	54.83	54.62	57.86	53.77	53.01	54.07	58.87	52.05
Profit Before Tax ⓘ	-98.95	2.15	18.42	-61.33	-0.15	-345.79	47.32	54.21	72.41	101.19
Tax ⓘ	-16.34	4.57	-1.16	-7.41	-19.29	-9.63	11.76	8.92	18.21	26.06
Profit After Tax	-82.62	-2.42	19.58	-53.92	19.14	-336.16	35.56	45.29	54.20	75.13
PAT Margin (%)	-15.3%	-0.4%	2.8%	-8.2%	3.0%	-55.8%	5.3%	6.3%	6.9%	9.2%
Adjusted EPS (₹)	-4.9	-0.1	1.2	-3.2	1.2	-20.3	0.7	0.9	1.1	1.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Fresenius Kabi Oncol - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	440.53	438.35	458.17	406.84	395.64	58.53	1,230.69	1,279.73	1,335.24	1,411.36
Share Capital ⓘ	17.02	17.02	17.02	17.02	16.52	16.52	48.04	48.04	48.04	48.04
Reserves ⓘ	423.51	421.33	441.15	389.82	379.12	42.01	1,182.65	1,231.69	1,287.20	1,363.32
Debt +	421.25	520.80	474.47	462.87	476.50	395.85	29	150.75	29	88.72
Long Term Debt	170.38	308.46	308.46	308.46	308.46	139.46	29	150.75	29	0
Short Term Debt	250.86	212.34	166.01	154.41	168.04	256.39	0	0	0	88.72
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	197.60	160.89	163.96	222.22	240.89	258.14	252.17	289.64	275.21	81.51
Others Liabilities ⓘ	119.56	227.40	263.34	262.38	223.63	721.50	164.08	212.12	354.05	293.06
Total Liabilities ⓘ	1,178.94	1,347.43	1,359.94	1,354.31	1,336.65	1,434.02	1,675.94	1,932.25	1,993.51	1,874.66
Fixed Assets
Net Fixed Assets ⓘ +	522.35	494.26	468.72	456.48	419.83	401.09	402.75	383.42	355.59	360.71
Gross Block	574.38	594.83	641.47	686.62	687.64	715.41	760.03	773.90	790.79	824.63
Accumulated Depreciation	52.03	100.57	172.75	230.14	267.82	314.31	357.28	390.48	435.20	463.92
CWIP ⓘ	30.39	44.64	37.55	37.02	24.83	25.17	38.78	135.22	157.06	171.42
Investments ⓘ	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Inventories	384.41	399.50	382.23	386.01	439.13	471.51	510.39	582.18	598.69	572.83
Trade Receivables	133.33	142.74	162.16	149.27	153.96	223.59	355.49	381.51	350.19	380.20
Cash Equivalents	2.34	8.26	1.64	1.97	0.78	4.83	30.14	59.18	170.54	5.39
Others Assets ⓘ	106.10	257.99	307.62	323.54	298.10	307.80	338.37	390.72	361.41	384.09
Total Assets ⓘ	1,178.94	1,347.43	1,359.94	1,354.31	1,336.65	1,434.02	1,675.94	1,932.25	1,993.51	1,874.66

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	7.93	-39.12	111.63	98.41	77.01	0.02	-459.75	23.68	174.54	-63.76
PBT ⓘ	-98.95	2.15	18.42	-61.33	-0.15	-345.79	47.32	54.21	72.41	101.19
Adjustment ⓘ	88.39	69.59	119.31	96.51	114.15	103.05	61.95	64.29	65.92	49.51
Changes in Working Capital ⓘ	18.69	-110.48	-19.82	66.68	-36.94	242.83	-568.87	-94.63	36.8	-214.11
Tax Paid ⓘ	-0.20	-0.37	-6.28	-3.46	-0.06	-0.07	-0.15	-0.19	-0.60	-0.34
Cash Flow From Investing Activity ⓘ +	-39.16	-32.69	-28.03	-52.21	-46.24	-44.58	-58.89	-96.26	-57.72	-46.22
Capex	-36.88	-39.51	-36.85	-54.47	-45.54	-49.39	-59.88	-98.98	-61.21	-48.32
Net Investments	0	10.22	1.08	1.48	-0.10	2.69	-0.04	0.50	-1.22	0.26
Others ⓘ	-2.28	-3.40	7.74	0.78	-0.61	2.12	1.03	2.22	4.71	1.85
Cash Flow From Financing Activity ⓘ +	-47.58	147.43	-29	-10.05	-32.97	49.12	556.14	102.07	-6.69	-77.73
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	1,134.70	0	0	0
Net Proceeds from Borrowing ⓘ	60	138.08	0	0	0	29	-308.46	0	0	0
Interest Paid ⓘ	-28.58	-30.65	-37	-33.05	-36.23	-32.48	-18.98	-3	-4.40	-8.48
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-79	40	8	23	3.25	52.59	-251.13	105.07	-2.29	-69.24
Net Cash Flow ⓘ	-78.81	75.62	54.60	36.14	-2.21	4.56	37.50	29.49	110.13	-187.70

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-17.16	-0.55	4.37	-12.47	4.77	-148.03	5.52	3.61	4.15	5.47
ROCE (%)	-8.05	4.26	6.8	-2.72	4.56	-40.47	6.67	4.77	5.42	7.33
Asset Turnover Ratio	0.46	0.5	0.52	0.49	0.47	0.44	0.43	0.4	0.4	0.42
PAT to CFO Conversion(x)	N/A	N/A	5.7	N/A	4.02	N/A	-12.93	0.52	3.22	-0.85
Working Capital Days
Receivable Days	82.90	79.40	78.80	86.20	87.90	114.30	158.40	187.60	169.80	164
Inventory Days	238.90	225.40	202	212.60	239.10	275.80	268.60	278	274	263
Payable Days	274.30	249.50	216.70	261.80	347.10	398.30	330.10	301.70	286.30	179.40

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Fresenius Kabi Oncology Ltd FAQs

The current trading price of Fresenius Kabi Oncol on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Fresenius Kabi Oncol stood at ₹2,254.9 Cr

The latest P/E ratio of Fresenius Kabi Oncol as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Fresenius Kabi Oncol as of 31-Dec-1969 is 3.87.

The 52-week high of Fresenius Kabi Oncol is ₹132.6 and the 52-week low is ₹132.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fresenius Kabi Oncol is ₹660 ( Cr.) .

Data is not available for this company.

No data found

About Fresenius Kabi Oncology Ltd

Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading supplier of IV generic drugs.

The company markets its products to various part of world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia, Kazakhstan, Uzbekistan, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Venezuela, Mexico, and many more.

The manufacturing facilities are located in Bordon (U.K.), Kalyani (India) and Baddi (India). These plants are approved by the regulatory bodies of countries like Brazil, Colombia, Malaysia, Turkey, Pakistan, Ukraine, Sudan, Belarus Hungary, Jordan, Zimbabwe, Yemen.

Products

APIs- It manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.

Oncology- Under this it has created drugs like Intaxel, Nanoxel.

Other range of generic products offered by Fresenius Kabi Oncology includes, Taxane Analogues, Alkylating Agents, Anti-Metabolites, Cytostatic Antibiotics, Cytostatic hormone therapies.

Fresenius Kabi Oncology Ltd (FKONCO)

Fresenius Kabi Oncology Ltd (FKONCO)

Fresenius Kabi Oncology stock performance

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Fresenius Kabi Oncol - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Fresenius Kabi Oncology Ltd FAQs

About Fresenius Kabi Oncology Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Fresenius Kabi Oncology Ltd (FKONCO)

Fresenius Kabi Oncology Ltd (FKONCO)

Fresenius Kabi Oncology stock performance

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Fresenius Kabi Oncol - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Fresenius Kabi Oncology Ltd FAQs

What is the share price of Fresenius Kabi Oncol?

What is the market cap of Fresenius Kabi Oncol?

What is the P/E ratio of Fresenius Kabi Oncol?

What is the P/B ratio of Fresenius Kabi Oncol?

What is the 52-week high and low of Fresenius Kabi Oncol?

What is the TTM revenue of Fresenius Kabi Oncol?

Is a good quality company?

Is undervalued or overvalued?

Is a good buy now?

About Fresenius Kabi Oncology Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.